Ozanimod hydrochloride

盐酸奥扎莫德

Report date: 2026/04/29 20:02:18
NME

Base Information

Drug NameOzanimod hydrochloride
Drug Alias NameOzanimod HClZeposia热珀西亚CYM-5442RPC-1063 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSphingosine 1-Phosphate Receptor 1 modulatorsSphingosine 1-phosphate receptor 5 modulators
TargetsSphingosine 1-phosphate receptor 5Sphingosine 1-Phosphate Receptor 1
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Multiple Sclerosis, Relapsing-RemittingMultiple Sclerosis +[8] 
Global Approved IndicationsMultiple Sclerosis, Relapsing-RemittingMultiple SclerosisColitis, Ulcerative
Approved Indications in ChinaMultiple Sclerosis
Original Approved Country/TerritoryUnited States
Original Approved Date2020/03/25
Country/TerritoryCzechiaBelgiumBosnia and Herzegovina +[54] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesThe Scripps Research Institute Inc
China Registration ClassN/A

Develop Information

Active CompaniesCelgene International Ii SarlBristol Myers Squibb SrlcompanyBristol-Myers Squibb (China) Investment Co Ltd +[10] 
Inactive CompaniesUniversity Institute Of Cardiology And Respirology Of QuebecCelgene International Sàrl
Active IndicationsMultiple Sclerosis, Relapsing-RemittingMultiple SclerosisLiver Diseases +[6] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Digestive System Diseases

Other Information

ATC CodeL04AE02
Related LinksWikipediaDrugBankKEGG